EXAS Exact Sciences Corporation

85.9
-2.16  -2%
Previous Close 88.06
Open 87.89
Price To Book 16.91
Market Cap 12,647,236,445
Shares 147,232,089
Volume 2,598,347
Short Ratio
Av. Daily Volume 2,264,563
Stock charts supplied by TradingView

NewsSee all news

  1. Exact Sciences Announces Preliminary Fourth Quarter 2019 Results

    MADISON, Wis., Jan. 12, 2020 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS) today announced that the company expects to report revenue between $294 million and $296 million for the fourth quarter ended Dec. 31,

  2. Exact Sciences to participate in J.P. Morgan Healthcare Conference

    MADISON, Wis., Jan. 2, 2020 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS) today announced that company management will participate in the following investor conference and invited investors to participate by

  3. Dr. David Ahlquist, co-inventor of Cologuard, named a Fellow of the National Academy of Inventors

    MADISON, Wis. and ROCHESTER, Minn., Dec. 4, 2019 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS) today announced Dr. David Ahlquist, co-inventor of Cologuard® and emeritus professor of medicine in the Division of

  4. Exact Sciences to participate in December investor conference

    MADISON, Wis., Nov. 26, 2019 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS) today announced that company management will be participating in the following investor conference. Evercore

  5. Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company

    Combined company joins two leading brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth MADISON, Wis., Nov. 8, 2019 /PRNewswire/ -- Exact Sciences Corp.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved August 2014
Cologuard
Cancer - Colorectal DNA test

Latest News

  1. Exact Sciences Announces Preliminary Fourth Quarter 2019 Results

    MADISON, Wis., Jan. 12, 2020 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS) today announced that the company expects to report revenue between $294 million and $296 million for the fourth quarter ended Dec. 31,

  2. Exact Sciences to participate in J.P. Morgan Healthcare Conference

    MADISON, Wis., Jan. 2, 2020 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS) today announced that company management will participate in the following investor conference and invited investors to participate by

  3. Dr. David Ahlquist, co-inventor of Cologuard, named a Fellow of the National Academy of Inventors

    MADISON, Wis. and ROCHESTER, Minn., Dec. 4, 2019 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS) today announced Dr. David Ahlquist, co-inventor of Cologuard® and emeritus professor of medicine in the Division of

  4. Exact Sciences to participate in December investor conference

    MADISON, Wis., Nov. 26, 2019 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS) today announced that company management will be participating in the following investor conference. Evercore

  5. Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company

    Combined company joins two leading brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth MADISON, Wis., Nov. 8, 2019 /PRNewswire/ -- Exact Sciences Corp.

  6. Exact Sciences Presents Data On Blood-Based Test For Detection Of Hepatocellular Carcinoma, Earns FDA Breakthrough Device Designation

    BOSTON, Nov. 8, 2019 /PRNewswire/ -- (NASDAQ:EXAS) – A new study of 443 patients by Exact Sciences Corp. and its collaborators demonstrated 80% sensitivity at 90% specificity with a novel combination of six blood-based

  7. Genomic Health Stockholders Approve Proposed Acquisition by Exact Sciences

    REDWOOD CITY, Calif., Nov. 7, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ:GHDX) announced that its stockholders voted to approve the company's proposed combination with Exact Sciences Corp (NASDAQ:EXAS) at a

  8. Shenandoah Telecommunications Set to Join S&P SmallCap 600

    NEW YORK, Nov. 4, 2019 /PRNewswire/ -- Shenandoah Telecommunications Co. (NASD: SHEN) will replace Genomic Health Inc. (NASD: GHDX) in the S&P SmallCap 600 effective prior to the open of trading on Friday, November

  9. Exact Sciences to participate in November investor conferences

    MADISON, Wis., Nov. 1, 2019 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS) today announced that company management will be presenting at the following investor conferences and invited investors to participate by

  10. Exact Sciences reports third-quarter revenue growth of 85 percent to $219 million

    MADISON, Wis., Oct. 29, 2019 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS) today announced that the company generated revenue of $218.8 million and screened approximately 456,000 people with Cologuard during the

  11. Exact Sciences Presents New Stool-Based Colorectal Cancer Screening Performance Data, Initiates Prospective Screening Study

    MADISON, Wis., Oct. 29, 2019 /PRNewswire/ -- (NASDAQ:EXAS) – Promising research from Exact Sciences Corp. and Mayo Clinic shows new methylation and protein markers detect colorectal cancer and advanced adenomas with high

  12. Exact Sciences And Mayo Clinic Initiate 150,000 Patient, 7-Year Study To Evaluate Real-World Impact Of Cologuard®

    MADISON, Wis., Oct. 14, 2019 /PRNewswire/ -- (NASDAQ:EXAS) – Exact Sciences Corp. today announced that, in collaboration with Mayo Clinic, it has initiated the Voyage study to generate evidence of the real-world impact

  13. Exact Sciences schedules third-quarter 2019 earnings call

    MADISON, Wis., Oct. 8, 2019 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS) today announced that the company plans to release its third-quarter 2019 financial results after the close of the U.S. financial markets on

  14. Cologuard® Gains FDA Approval For Use In Younger Americans, Ages 45 To 49

    MADISON, Wis., Sept. 23, 2019 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS) announced today that the U.S. Food and Drug Administration (FDA) approved its noninvasive colorectal cancer screening test, Cologuard, for

  15. Exact Sciences Named One of the 2019 Best Workplaces for Women by Great Place to Work® and FORTUNE

    MADISON, Wis., Sept. 19, 2019 /PRNewswire/ -- Exact Sciences is a member of the 2019 Best Workplaces for Women list, an honor given by Great Place to Work® and FORTUNE to employers providing supportive, inclusive

  16. Patrick Terry announced as first Chief Commercial Officer of SomaLogic

    Boulder, Colo., Sept. 10, 2019 (GLOBE NEWSWIRE) -- SomaLogic announced today that Patrick Terry has joined the company as its first Chief Commercial Officer (CCO).

  17. Cologuard® Helps More People Get Screened In A Cost-Effective Way

    MADISON, Wis., Sept. 10, 2019 /PRNewswire/ -- (NASDAQ:EXAS) -- Exact Sciences announced today that nearly 3 million people have been screened for colorectal cancer with Cologuard since FDA approval with half of those

  18. Exact Sciences to participate in September investor conference

    MADISON, Wis., Aug. 30, 2019 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS) today announced that company management will be presenting at the following investor conference and invited investors to participate by